Does TOPOTECAN Cause Interstitial lung disease? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Interstitial lung disease have been filed in association with TOPOTECAN (HYCAMTIN). This represents 0.5% of all adverse event reports for TOPOTECAN.
16
Reports of Interstitial lung disease with TOPOTECAN
0.5%
of all TOPOTECAN reports
13
Deaths
4
Hospitalizations
How Dangerous Is Interstitial lung disease From TOPOTECAN?
Of the 16 reports, 13 (81.3%) resulted in death, 4 (25.0%) required hospitalization, and 1 (6.3%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for TOPOTECAN.
What Other Side Effects Does TOPOTECAN Cause?
Febrile neutropenia (425)
Off label use (390)
Death (332)
Product use in unapproved indication (323)
Neutropenia (255)
Pyrexia (252)
Anaemia (242)
Malignant neoplasm progression (238)
Drug ineffective (216)
Disease progression (207)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TOPOTECAN Alternatives Have Lower Interstitial lung disease Risk?
TOPOTECAN vs TOPOTECAN\TOPOTECAN
TOPOTECAN vs TOPROL
TOPOTECAN vs TOREMIFENE
TOPOTECAN vs TORIPALIMAB
TOPOTECAN vs TORSEMIDE